Combining GOT1 inhibitors with other anticancer agents may enhance its therapeutic efficacy, particularly in cases where pancreatic cancer exhibits resistance to existing treatments, making GOT1 inhibition a potentially effective complementary strategy [106]. This evidence concerns the gene GOT1 and familial pancreatic carcinoma.